Re: Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma

Samir S. Taneja

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Pages (from-to)413-414
Number of pages2
JournalJournal of Urology
Volume188
Issue number2
DOIs
StatePublished - Aug 2012

ASJC Scopus subject areas

  • Urology

Cite this